The performance of two commercial phospho-tau217 (p-tau217) assays.
By Tarun Sai LomteMar 14 2024Reviewed by Lily Ramsey, LLM In a recent study published in eBioMedicine, researchers compared the performance of two commercial phospho-tau217 assays.
Further, plasma biomarkers can aid in the identification of advanced tau pathology. p-tau217 is a potential blood-based biomarker for AD due to its strong correlations with tau and amyloid pathologies, diagnostic performance, and equivalence with established cerebrospinal fluid biomarkers. Clinical diagnosis was performed before acquiring biomarker data in the cohort; cognitively unimpaired individuals had clinical dementia rating and mini-mental state examination scores of 0 and > 24, respectively.
Sex proportions and age were compared between groups using the chi-squared test and analysis of variance. Spearman rank tests determined correlations between biomarkers. Both assays exhibited robust correlations with CSF p-tau217 and amyloid PET SUVR. Voxel-wise analyses showed that the two assays had similar topographical association patterns between plasma amyloid PET and p-tau217.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Study opens the door to earlier diagnosis and potential treatment for Alzheimer's diseaseA study might open the door to earlier diagnosis and a potential pathway toward slowing the progression of Alzheimer's disease. Researchers have discovered a special receptor on immune cells that can effectively bind and neutralize harmful 'beta proteins,' which are strongly associated with the disease.
続きを読む »
Wristwatch-like devices detect early signs of Alzheimer'sMonitoring daily activity patterns using a wrist-worn device may detect early warning signs of Alzheimer's disease, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
続きを読む »
Nutrition's crucial role in Alzheimer's progression revealedStudy highlights the strong association between nutrition, particularly malnutrition, and the risk and progression of Alzheimer's disease, emphasizing early dietary interventions as key to reducing AD's global burden.
続きを読む »
FDA delays decision on new Alzheimer's drugInstead of approving the new Alzheimer's drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely by an expert panel, the drug's maker said Friday.
続きを読む »
Highly awaited Alzheimer's drug hit by delaysEli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
続きを読む »
PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s DiseasesNew collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions.
続きを読む »